Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01782053 · ClinicalTrials.gov registry record · Phase 3
Communicating Smoking Risks Through Graphic Warning Labels
A Phase 3 study of Lung Cancer and Heart Disease, sponsored by University of Pennsylvania.
- Completed
- Registry status
- Phase 3
- Development phase
- 245
- Enrollment target
- 2
- Study locations
NCT01782053 is a Phase 3 study of Lung Cancer and Heart Disease that has completed, run by University of Pennsylvania. The registered enrollment target is 245 participants, below the 935-participant average among 409 other Lung Cancer trials with a reported enrollment target (74% lower). The trial reports 2 study locations across 2 states.
The verdict
NCT01782053, a Phase 3 study of Lung Cancer and Heart Disease, has completed, sponsored by University of Pennsylvania.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 245 participants
- Enrollment target
- 2
- Study locations
Study Summary
Smoking is the largest preventable health risk in the U.S. The Family Smoking Prevention and Tobacco Control Act of 2010 mandated the placement of larger pictorial warnings on cigarette packs as well as nine new statements of smoking risks. This trial tests the effectiveness of the warnings proposed by the Food and Drug Administration by providing cigarettes with the proposed labels to 320 smokers across two sites (Philadelphia, PA and Columbus, OH). In addition, the trial tests the effects of different warning label components.
Conditions Studied
Interventions
- BEHAVIORAL Control
- BEHAVIORAL Picture warning
Study Locations (2)
Ohio
- Lazenby Hall, Ohio State University - Columbus
Pennsylvania
- Annenberg Public Policy Center - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 245 participants |
| Start Date | 2013-01 |
| Est. Completion | 2014-04 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01782053
The ClinicalTrials.gov registry entry for NCT01782053 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 245 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 935-participant average among 409 other Lung Cancer trials with a reported enrollment target (74% lower). The listed sponsor is University of Pennsylvania, which has 1,423 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Lung Cancer appearing as the primary indexed condition, and to 2 interventions - of which Control is the first listed.
NCT01782053 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Ohio, Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT01782053 about?
NCT01782053 is a clinical study titled "Communicating Smoking Risks Through Graphic Warning Labels". Smoking is the largest preventable health risk in the U.S. The Family Smoking Prevention and Tobacco Control Act of 2010 mandated the placement of larger pictorial warnings on cigarette packs as well as nine new statements of smoking risks. This trial tests the effectiveness of the warnings proposed...
What is the current status of trial NCT01782053?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 245 participants. The study started on 2013-01. Estimated completion is 2014-04.
What conditions does trial NCT01782053 study?
This clinical trial studies the following conditions: Lung Cancer, Heart Disease.
What interventions are being tested in trial NCT01782053?
The interventions under investigation include: Control (BEHAVIORAL), Picture warning (BEHAVIORAL).
Who is sponsoring clinical trial NCT01782053?
This trial is sponsored by University of Pennsylvania, which has 1,423 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01782053 being conducted?
This trial has 2 study locations across Ohio, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Stereotactic Ablative Radiotherapy (SABR) for the Treatment of Patients With Metastatic Cancer, ID-COMET Trial
RECRUITING · Phase 3
-
A Study to Assess the Efficacy and Safety of Zipalertinib Versus Placebo for Adjuvant Treatment in Participants With Stage IB-IIIA NSCLC With Uncommon EGFR Mutations, Following Complete Tumor Resection
RECRUITING · Phase 3
-
A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
RECRUITING · Phase 3
-
A Clinical Study of Pembrolizumab (+) Berahyaluronidase Alfa (MK-3475A) to Treat Newly-diagnosed Metastatic Non-small Cell Lung Cancer (MK-3475A-F84)
ACTIVE NOT RECRUITING · Phase 3
-
Stereotactic Radiation Therapy With or Without Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases
COMPLETED · Phase 3
-
Gemcitabine and Carboplatin Followed By Docetaxel in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer
COMPLETED · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.